Correction: Private placement of 25,000,000 new shares fully subscribed – gross proceeds of DKK 33.5 million, to BioPorto A/S

Core Insights - BioPorto A/S has successfully completed a private placement of 25,000,000 new shares, raising gross proceeds of DKK 33.5 million [1][3] - The CEO expressed satisfaction with the strong support from existing and new investors, which will facilitate the company's strategic initiatives, including financing clinical trials for FDA clearance of ProNephro AKI™ NGAL [2][5] - The new shares are expected to be listed on Nasdaq Copenhagen by April 30, 2025 [3] Company Overview - BioPorto is an in vitro diagnostics company focused on early detection of Acute Kidney Injury (AKI) through actionable biomarkers [5][6] - The company's flagship products utilize the NGAL biomarker to aid in the risk assessment and diagnosis of AKI, enabling earlier intervention and tailored patient management [6][7] - BioPorto operates facilities in Copenhagen, Denmark, and Boston, MA, USA, and is listed on the Nasdaq Copenhagen stock exchange [7]